News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
749,298 Results
Type
Article (44275)
Company Profile (467)
Press Release (704543)
Multimedia
Podcasts (149)
Webinars (23)
Section
Business (209551)
Career Advice (2049)
Deals (36237)
Drug Delivery (140)
Drug Development (84172)
Employer Resources (174)
FDA (16813)
Job Trends (15233)
News (354748)
Policy (33310)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (4)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (6)
Academia (2691)
Accelerated approval (55)
Adcomms (31)
Allergies (181)
Alliances (51116)
ALS (226)
Alzheimer's disease (1874)
Antibody-drug conjugate (ADC) (514)
Approvals (17196)
Artificial intelligence (723)
Autoimmune disease (326)
Automation (58)
Bankruptcy (374)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (228)
Biotechnology (325)
Bladder cancer (205)
Brain cancer (77)
Breast cancer (802)
Cancer (6247)
Cardiovascular disease (507)
Career advice (1743)
Career pathing (45)
CAR-T (357)
CDC (60)
Celiac Disease (3)
Cell therapy (974)
Cervical cancer (51)
Clinical research (73074)
Collaboration (2225)
Company closure (5)
Compensation (1463)
Complete response letters (93)
COVID-19 (2813)
CRISPR (120)
C-suite (1218)
Cystic fibrosis (163)
Data (8414)
Decentralized trials (3)
Denatured (46)
Depression (176)
Dermatology (94)
Diabetes (616)
Diagnostics (7045)
Digital health (59)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (353)
Drug pricing (213)
Drug shortages (32)
Duchenne muscular dystrophy (314)
Earnings (93478)
Editorial (71)
Employer branding (21)
Employer resources (153)
Events (123943)
Executive appointments (1135)
FDA (20697)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (36)
Funding (1846)
Gene editing (259)
Generative AI (58)
Gene therapy (795)
GLP-1 (1114)
Government (4846)
Grass and pollen (6)
Guidances (415)
Healthcare (19456)
HIV (84)
Huntington's disease (59)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (109)
Immunology and inflammation (323)
Immuno-oncology (108)
Indications (201)
Infectious disease (3172)
Inflammatory bowel disease (229)
Inflation Reduction Act (17)
Influenza (140)
Intellectual property (306)
Interviews (319)
IPO (16959)
IRA (53)
Job creations (3719)
Job search strategy (1443)
JPM (67)
Kidney cancer (19)
Labor market (105)
Layoffs (601)
Leadership (42)
Legal (8033)
Liver cancer (104)
Longevity (34)
Lung cancer (836)
Lymphoma (450)
Machine learning (61)
Management (59)
Manufacturing (1103)
MASH (209)
Medical device (14106)
Medtech (14244)
Mergers & acquisitions (20539)
Metabolic disorders (1618)
mRNA (245)
Multiple sclerosis (198)
NASH (20)
Neurodegenerative disease (466)
Neuropsychiatric disorders (115)
Neuroscience (3511)
Neurotech (1)
NextGen: Class of 2026 (6774)
Non-profit (4606)
Now hiring (79)
Obesity (765)
Opinion (314)
Ovarian cancer (237)
Pain (266)
Pancreatic cancer (333)
Parkinson's disease (396)
Partnered (34)
Patents (617)
Patient recruitment (717)
Peanut (65)
People (61173)
Pharmaceutical (79)
Pharmacy benefit managers (34)
Phase 1 (22988)
Phase 2 (32251)
Phase 3 (23806)
Pipeline (9368)
Policy (341)
Postmarket research (2607)
Preclinical (9853)
Press Release (67)
Prostate cancer (332)
Psychedelics (64)
Radiopharmaceuticals (361)
Rare diseases (1177)
Real estate (6084)
Recruiting (71)
Regulatory (26109)
Reports (56)
Research institute (2517)
Resumes & cover letters (355)
Rett syndrome (39)
RNA editing (28)
RSV (88)
Schizophrenia (187)
Series A (315)
Series B (229)
Service/supplier (11)
Sickle cell disease (124)
Special edition (29)
Spinal muscular atrophy (171)
Sponsored (49)
Startups (3838)
State (2)
Stomach cancer (19)
Supply chain (132)
Tariffs (88)
The Weekly (100)
Vaccines (1155)
Venture capital (122)
Weight loss (495)
Women's health (133)
Worklife (21)
Date
Today (133)
Last 7 days (764)
Last 30 days (3484)
Last 365 days (31104)
2026 (14551)
2025 (31061)
2024 (36287)
2023 (41011)
2022 (52276)
2021 (56759)
2020 (54917)
2019 (47413)
2018 (35693)
2017 (33022)
2016 (32347)
2015 (38396)
2014 (32185)
2013 (27110)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (759)
Alabama (99)
Alaska (7)
Arizona (364)
Arkansas (16)
Asia (41292)
Australia (6879)
California (13883)
Canada (3877)
China (1469)
Colorado (594)
Connecticut (617)
Delaware (423)
Europe (90876)
Florida (2045)
Georgia (443)
Hawaii (3)
Idaho (63)
Illinois (1123)
India (93)
Indiana (623)
Iowa (25)
Japan (568)
Kansas (136)
Kentucky (52)
Louisiana (45)
Maine (76)
Maryland (1653)
Massachusetts (10043)
Michigan (374)
Minnesota (750)
Mississippi (6)
Missouri (148)
Montana (35)
Nebraska (29)
Nevada (145)
New Hampshire (89)
New Jersey (3643)
New Mexico (32)
New York (3609)
North Carolina (1814)
North Dakota (10)
Northern California (6970)
Ohio (413)
Oklahoma (23)
Oregon (44)
Pennsylvania (2763)
Puerto Rico (29)
Rhode Island (52)
South America (1126)
South Carolina (86)
South Dakota (2)
Southern California (5465)
Tennessee (217)
Texas (2201)
United States (49064)
Utah (411)
Vermont (1)
Virginia (335)
Washington D.C. (82)
Washington State (1134)
West Virginia (4)
Wisconsin (135)
Wyoming (2)
749,298 Results for "sarepta therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Sarepta says to ‘exercise prudence’ in setting expectations for Elevidys’ recovery
Sarepta Therapeutics has put in place several initiatives to help its gene therapy Elevidys return to growth, but recovery will take a long time, according to company executives.
May 7, 2026
·
2 min read
·
Tristan Manalac
Earnings
After Sarepta’s Annus Horribilis, Elevidys Sales Expected To Continue Downward Spiral
After a rocky 2025, Sarepta Therapeutics’ executives admit they have work to do to bring patients back into the fold as sales of Duchenne muscular dystrophy gene therapy Elevidys continue to decline.
February 26, 2026
·
5 min read
·
Annalee Armstrong
Press Releases
Sarepta Therapeutics to Participate in Upcoming June 2026 Investor Conferences
June 2, 2026
·
1 min read
Pipeline
Sarepta Pushes Past Gene Therapy Debacle as RNA Therapies Show Early Promise
Biomarker data for Sarepta Therapeutics’ RNA programs, licensed from Arrowhead Pharmaceuticals, are “competitive” and “strong,” according to analysts at Jefferies, which projected over $1 billion in peak sales.
March 26, 2026
·
2 min read
·
Tristan Manalac
FDA
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure
Sarepta Therapeutics says the FDA has agreed to review a regulatory package for Amondys 45 and Vyondys 53 after they failed a confirmatory trial, but whether the agency will agree to approve them is still unknown.
March 19, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
May 14, 2026
·
1 min read
Duchenne muscular dystrophy
Following Sarepta Woes, Others Look To Unlock the Next Chapter in DMD Treatment
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor Therapeutics, CureDuchenne CSO Michael Kelly sees “momentum” in the Duchenne muscular dystrophy pipeline, as Sarepta’s Elevidys leaves the door open.
February 9, 2026
·
11 min read
·
Heather McKenzie
Opinion
Balancing Safety Access in Rare Disease—Lessons From Sarepta
Regulators overseeing rare disease treatments need better tools to weigh competing risks in real time. Sarepta Therapeutics’ Elevidys is a prime example of why.
February 25, 2026
·
6 min read
·
Joshua R. Mansbach
C-suite
Sarepta CEO Doug Ingram To Step Down as Muscular Dystrophy Mission Hits Home
When Ingram became Sarepta Therapeutics’ CEO in 2017, he didn’t have a connection to muscular dystrophy, but he has developed a fierce passion for the therapeutic area. He will step aside from his role to dedicate more time to his family.
February 25, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
April 23, 2026
·
1 min read
1 of 74,930
Next
